A5000233437- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Neuroscience and Neuropharmacology Research
- EEG and Brain-Computer Interfaces
- Pharmaceutical studies and practices
- Neurological disorders and treatments
- Ion channel regulation and function
- Functional Brain Connectivity Studies
- Fetal and Pediatric Neurological Disorders
- Genetics and Neurodevelopmental Disorders
- Mitochondrial Function and Pathology
- Neonatal and fetal brain pathology
- Transcranial Magnetic Stimulation Studies
- Diet and metabolism studies
- Electrochemical Analysis and Applications
- Antibiotics Pharmacokinetics and Efficacy
- Drug Transport and Resistance Mechanisms
- Attention Deficit Hyperactivity Disorder
- Anesthesia and Sedative Agents
- Metabolism and Genetic Disorders
- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Pregnancy and Medication Impact
- Analytical Methods in Pharmaceuticals
- Glioma Diagnosis and Treatment
University of Washington
2016-2025
Valley Medical Center
2010-2023
Renton Technical College
2022
University of Washington Medical Center
2013-2019
Santa Clara Valley Medical Center
2013-2019
Swedish Medical Center
1993-2004
Swedish Medical Center
1993-1997
Boston Medical Center
1990
Boston University
1990
Harborview Medical Center
1990
Summary Objective Evaluate the seizure‐reduction response and safety of mesial temporal lobe ( MTL ) brain‐responsive stimulation in adults with medically intractable partial‐onset seizures origin. Methods Subjects epilepsy MTLE were identified from prospective clinical trials a neurostimulator RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing frequency compared to preimplantation baseline. Safety assessed based on reported adverse...
Summary Objective Evaluate the seizure‐reduction response and safety of brain‐responsive stimulation in adults with medically intractable partial‐onset seizures neocortical origin. Methods Patients partial origin were identified from prospective clinical trials a neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing frequency compared to preimplantation baseline. Safety assessed based on reported adverse events. Additional...
Abstract Objective During the development of cenobamate, an antiseizure medication (ASM) for focal seizures, three cases drug reaction with eosinophilia and systemic symptoms (DRESS) occurred. To mitigate rate DRESS, a start‐low, go‐slow approach was studied in ongoing, open‐label, multicenter study. Also examined were long‐term safety cenobamate method managing pharmacokinetic interaction between 2C19 inhibitor, concomitant phenytoin or phenobarbital. Methods Patients 18‐70 years old...
Objective To evaluate efficacy and safety of lacosamide (up to 12 mg/kg/day or 400 mg/day) as adjunctive treatment for uncontrolled primary generalised tonic-clonic seizures (PGTCS) in patients (≥4 years) with idiopathic epilepsy (IGE). Methods Phase 3, double-blind, randomised, placebo-controlled trial (SP0982; NCT02408523 ) IGE PGTCS taking 1–3 concomitant antiepileptic drugs. Primary outcome was time second during 24-week treatment. Results 242 were randomised received ≥1 dose medication...
The International League Against Epilepsy (ILAE) / American Society (AES) Task Force on the cardiac effects of lamotrigine was convened in response to a recent addition label by US Food and Drug Administration (FDA).1 Lamotrigine is nonproprietary name for medicine that sold under its generic several brand names including Lamictal™. present advisory based an assessment currently available evidence. It not intended replace regulatory requirements, nor it be exhaustive review. Its purpose...
Abstract Objective To report long‐term post hoc efficacy and safety data from 10 US study sites an open‐label Phase 3 of adjunctive cenobamate (NCT02535091). Methods Patients with uncontrolled focal seizures taking stable doses 1–3 antiseizure medications (ASMs) were administered increasing daily (12.5, 25, 50, 100, 150, 200 mg/day) over 12 weeks at 2‐week intervals (target dose = mg/day). Further increases to 400 mg/day by 50‐mg/day increments biweekly allowed during the maintenance phase....
Abstract Objective To report post hoc results on how adjustments to baseline antiseizure medications (ASMs) in a subset of study sites (10 US sites) from long‐term, open‐label phase 3 adjunctive cenobamate affected tolerability, efficacy, and retention. Methods Patients with uncontrolled focal seizures taking stable doses one three ASMs were administered increasing (12.5, 25, 50, 100, 150, 200 mg/day) over 12 weeks at 2‐week intervals (target dose = mg/day). Further increases 400 mg/day by...
Importance Many patients with focal epilepsy experience seizures despite treatment currently available antiseizure medications (ASMs) and may benefit from novel therapeutics. Objective To evaluate the efficacy safety of XEN1101, a small-molecule selective Kv7.2/Kv7.3 potassium channel opener, in focal-onset (FOSs). Design, Setting, Participants This phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging adjunctive trial investigated XEN1101 over an 8-week period...
Summary: Purpose: To investigate ammonia and glutamine levels in valproate (VPA)‐related hyperammonemic encephalopathy (VHE). Methods: We reviewed the medical records EEG recordings of seven adults diagnosed with VHE. Results: Venous were elevated five (71%) patients. Elevated serum or cerebrospinal fluid (CSF) found four (80%) cases tested, including two who had normal levels. Initial behavioral signs included violent outbursts three patients, paranoid ideation severe enough to require...
NEUROSURGERY PUBLICATIONS OPERATIVE PRACTICE CNS.ORG
Norrie disease (ND) is an X-linked recessive disorder causing ocular atrophy, mental retardation, deafness, and dysmorphic features. Virtually absent monoamine oxidase (MAO) type-A -B activity has been found in some boys with chromosome deletions. We report the coexistence of cataplexy abnormal REM sleep organization ND. Three related boys, referred for treatment medically refractory atonic spells apneas, underwent extended EEG-video-polysomnographic monitoring. They demonstrated attacks...
To assess the efficacy and safety of eslicarbazepine acetate (ESL) monotherapy.This post hoc pooled analysis 2 randomized double-blind studies (093-045 -046) included adults with partial-onset seizures medically uncontrolled by 1 or antiepileptic drugs (AEDs). Following baseline period (8 weeks), eligible patients were 2:1 to receive ESL 1,600 mg 1,200 once daily for 18 weeks; primary endpoint was study exit meeting predefined criteria (signifying worsening seizure control). In each study,...
ABSTRACT Purpose To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive epilepsy (PME), an open‐label setting. Methods Thirty patients refractory PME (aged ≥ 5 years), who were taking up to three antiepileptic drugs, received adjunctive (≤ 6 mg/kg/day) therapy for 16 weeks. Myoclonic recorded daily over a 24‐hour period or 10‐minute epochs morning, afternoon, evening. Safety was assessed via adverse events (AEs); measured by percentage...